2+ channels (T-channels), especially Ca v 3.2 among the three isoforms (Ca v 3.1, Ca v 3.2, and Ca v 3.3), are now considered to play pivotal roles in processing of pain signals. Ca v 3.2 T-channels are functionally modulated by extracellular substances such as hydrogen sulfide and ascorbic acid, by intracellular signaling molecules including protein kinases, and by glycosylation. Ca v 3.2 T-channels are abundantly expressed in both peripheral and central endings of the primary afferent neurons, regulating neuronal excitability and release of excitatory neurotransmitters such as substance P and glutamate, respectively. Functional upregulation of Ca v 3.2 T-channels is involved in the pathophysiology of inflammatory, neuropathic, and visceral pain. Thus, Ca v 3.2 T-channels are considered to serve as novel targets for development of drugs for treatment of intractable pain resistant to currently available analgesics.
Introduction

T-type Ca
2+ channels (T-channels) are activated at near-resting membrane potential and play a crucial role in the neuronal firing. T-channels consist of a single pore-forming a 1 -subunit, differing from high-voltageactivated (HVA) Ca 2+ channels (L-, N-, P/Q-, and R-type Ca 2+ channels) that are heteromultimers comprising an a 1 -subunit together with ancillary b, g, and a 2 d subunits. Three a 1 -subunit genes, CACNA1G, CACNA1H, and CACNA1I, encode a 1G (Ca v 3.1), a 1H (Ca v 3.2) and a 1I (Ca v 3.3) isoforms of the T-channel family, respectively (1) . T-channels regulate neuronal excitability in the central and peripheral nervous systems, and hormone secretion under physiological conditions, whereas altered functions of T-channels are linked to pathophysiologies such as absence epilepsy, caridiovascular diseases, cancer, and pain (2) . In 2001, Todorovic and his coworkers (3) , for the first time, provided clear evidence for the involvement of T-channels in pain signaling, and thereafter a number of researchers including our group have demonstrated that Ca v 3.2 and possibly Ca v 3.1 play a pivotal role in nociceptive processing in health and disease (4) . We have demonstrated that Ca v 3.2 Tchannels are functionally upregulated by endogenous substances including hydrogen sulfide (H 2 S) and participate in not only somatic but also visceral pain signaling (5 -8) . Here we describe the molecular characteristics and functional modulation of T-channels, especially Ca v 3.2, and review their impacts on peripheral and central processing of somatic and visceral pain signals. selectively enhance the channel functions of Ca v 3.2 among the three T-channel isoforms, leading to nociceptor sensitization or hyperalgesia in vivo (4, 6, 9, 10) . H 2 S, a diffusible gasotransmitter, is synthesized from lcysteine by multiple enzymes such as cystathionine-glyase (CSE) (Fig. 1) , playing various roles in health and disease (11) The intracellular linker between domains II and III (II-III linker) of T-channels is considered a target site for modulation of the channel functions by various protein kinases including Ca 2+ /calmodulin-dependent protein kinase II (CaMKII), protein kinase A (PKA), PKC, and Rho-associated protein kinase (ROCK) (Fig. 1) (2, 14) . A serine residue at position 1198 (Ser 1198 ) within the II-III linker of Ca v 3.2 appears to be a key site for phosphorylation and functional potentiation of the channels by CaMKII (14) , whereas precise phosphorylation sites in the II-III linker for other protein kinases have not been identified. There is evidence that PKC and PKA enhance the activities of Ca v 3.1, Ca v 3.2, and Ca v 3.3 expressed in mammalian cell lines (2, 14) . However, several papers show suppression of T-channel activity by PKC (4, 14) (Fig. 1) , implying that effects of PKC on T-channels might vary with cell types, PKC isoforms, or other experimental conditions. On the other hand, PKA activation of T-channels appears to mediate various cellular responses to activation of G s protein-coupled receptors (2, 14) . Recently, we have demonstrated the molecular (Fig. 1) . AKAP-dependent facilitation of T-channel currents by cyclic AMP has also been demonstrated in isolated rat dorsal root ganglion (DRG) neurons (15), implying potential roles of PKA-mediated activation/ sensitization of T-channels in pain signaling. G 12/13 protein-dependent activation of RhoA and ROCK following stimulation of lysophosphatidic acid (LPA) receptors, a family of GPCRs, causes a shift of the activation and inactivation curves to the more depolarized potentials for Ca v 3.2, although it mediates reversible inhibition of Ca v 3.1 and Ca v 3.3 (2, 14) . The physio logical or pathological roles of 'sensitization' of Ca v 3.2 following LPA receptor activation ( Fig. 1 ) remain unclear, although LPA has been linked to neuropathic pain (14) . The II-III linker of T-channels is also a target for functional modulation by G bg subunits downstream of GPCRs (Fig. 1) . Stimulation of dopamine D 1 receptors expressed in adrenocarcinomal H295R cells causes direct interaction of G b2g2 subunits with Ca v 3.2, leading to inhibition of the channel functions (14) . Similarly, activation of corticotropin-releasing factor receptor 1 (CRFR 1 ) inhibits Ca v 3.2, but not Ca v 3.1 and Ca v 3.3, through a cholera toxin-sensitive, G bg -mediated pathway (2, 14).
Functional modulation of T-type
T-channel modulation by asparagine-linked glycosylation
Modulation of Ca v 3.2 T-channels by asparagine Nlinked glycosylation at positions 192 (Asn 192 ) and 1466 (Asn 1466 ) was recently reported (16) . Glycosylation at Asn 192 promotes channel expression of Ca v 3.2 at the cell surface, whereas glycosylation at Asn 1466 enhances the channel activity (Fig. 1) . Strikingly, N-linked glycosylation of Ca v 3.2 also underlies glucose-dependent potentiation of the channel functions, which might be implicated in diabetic neuropathy. It has yet to be studied whether N-glycans regulate functions of Ca v 3.1 or Ca v 3.3, although those two Asn residues at corresponding positions are conserved in all three T-channel isoforms (Fig. 1) .
Roles of T-channels in processing of pain signaling
Somatic pain processing by T-channels
After the first report concerning nociceptor sensitization by activation of T-channels (3), a critical role of Ca v 3.2 in sensory neurons was demonstrated by its gene silencing using the antisense oligodeoxynucleotides (17) . Further, a study using knockout mice (18) demonstrated involvement of Ca v 3.1 and Ca v 3.2 in nociceptive processing, particularly signaling of inflammatory pain (18) . Generally, it is considered that Ca v 3.2 T-channels regulate cellular excitability in the peripheral nerve endings of nociceptors, while N-type Ca 2+ channels regulate release of neurotransmitters such as glutamate and substance P in the central terminals of the nocicepor neurons in laminae I and II of the spinal dorsal horn (19) (Fig. 2) . However, the most recent evidence shows that Ca v 3.2 channels also regulate low-threshold exocytosis in cultured cells in an action potential-independent manner (20) and that presynaptic Ca v 3.2 regulates spontaneous excitatory synaptic neurotransmission in the spinal dorsal horn (21) . Thus, Ca v 3.2 is now considered to play important roles in nociceptive processing at both peripheral and central endings of the primary afferent neurons (Fig. 2) . This notion is consistent with our finding that not only intraplantar but also intrathecal administration of NaHS, a donor of H 2 S, caused hyperalgesia in rats, an effect blocked by a T-channel blocker or by silencing of the Ca v 3.2 gene (6). Activation/sensitization of Tchannels by endogenous H 2 S formed by CSE may be involved in inflammatory hyperalgesia because inhibitors of T-channels and CSE, an H 2 S-forming enzyme, prevent the development of inflammatory hyperalgesia caused by intraplantar administration of lipopolysaccharide (LPS) in rats (5) . It is also to be noted that H 2 S is capable of activating TRPA1 channels in addition to Ca v 3.2 (22) and that peripheral H 2 S-induced mechanical hyperalgesia and allodynia require activation of both Ca v 3.2 and TRPA1 (23) (Fig. 2) . AKAP-dependent functional upregulation of Ca v 3.2 by PKA following EP 4 receptor activation mediates PGE 2 -induced mechanical hyperalgesia (15) , although sensitization of TRPV1 channels by PKC following EP 1 -receptor activation participates in the PGE 2 -induced thermal hyperalgesia (24) (Fig. 2) . Thus, Ca v 3.2 expressed in the nociceptors appears to play a role in the development of inflammatory pain or hyperalgesia. There is also some evidence for pro-nociceptive roles of Ca v 3.2 at the supraspinal levels (25, 26) . A study shows that Ca v 3.2-dependent activation of ERK in the anterior nucleus of the paraventricular thalamus contributes to the development of acid-induced chronic hyperalgesia (25) . It has also been demonstrated that Ca v 3.2 is involved in the generation of burst firing of both nociceptive and tactile reticular thalamic neurons (26).
Involvement of T-channels in neuropathic pain
Accumulating evidence strongly suggests involvement of T-channels in neuropathic pain (4) . There is evidence for upregulation of T-channel current density in small DRG cells isolated from rats with neuropathic pain due to chronic constrictive injury (CCI) of the sciatic nerve (27) and that genetic silencing of Ca v 3.2 channels reverses CCI-induced neuropathic pain (17) . We have demonstrated upregulation of Ca v 3.2 at protein levels in the DRG of rats with neuropathy induced by spinal nerve injury and that pharmacological inhibition or genetic silencing of Ca v 3.2 reverses the established neuropathic hyperalgesia/allodynia (28) . Interestingly, the neuropathic pain caused by spinal nerve injury is also abolished by two distinct inhibitors of CSE, an H 2 S forming enzyme, suggesting that in addition to the upregulation of Ca v 3.2, sensitization of Ca v 3.2 by CSE-derived endogenous H 2 S through interaction with Zn 2+ , as described in Section 2.1. and shown in Fig. 1 , contributes to the neuropathic pain (28) . In addition to Ca v 3.2, Ca v 3.1 and Ca v 3.3 may be involved in the pathophysiology of neuropathic pain, considering evidence that neuropathic pain induced by L5 spinal nerve ligation is attenuated in Ca v 3.1-defective mice (29) and that Ca v 3.3, as well as Ca v 3.2, is upregulated at mRNA levels in the spinal cord of the rats with neuropathy induced by chronic compression of DRG (30) .
Many anticancer agents, such as vincristine, paclitaxel, and oxaliplatin, often cause painful peripheral neuropathies that limit their use in cancer therapy. Involvement of T-channels in cancer chemotherapy-induced neuropathy was first suggested by a report showing that systemic administration of ethosuximide, a classic T-channel inhibitor, alleviated mechanical and cold allodynia/ hyperalgesia in rats with paclitaxel-or vincristineinduced neuropathy (31) . We have confirmed that paclitaxel-induced neuropathic hyperalgesia is abolished by more selective inhibitors of T-channels and by Ca v 3.2 gene silencing, although expression levels of Ca v 3.2 in DRG do not change in this neuropathic pain model (32) , differing from the spinal nerve injury-induced neuropathic pain models in which Ca v 3.2 is dramatically upregulated in DRG (28) . It is also noteworthy that the paclitaxel-induced neuropathy is reversed by an inhibitor of CSE, suggesting involvement of functional upregulation of the CSE/H 2 S/Ca v 3.2 pathway. Strikingly, we have detected significant decrease in levels of ascorbic acid (vitamin C), known to selectively inhibit Ca v 3.2 (see Fig. 1 ), in the hindpaw tissue of rats with paclitaxelinduced neuropathy (13) . We have also shown that intraplantar injection of ascorbic acid or topical application of disodium isostearyl 2-O-l-ascorbyl phosphate (DI-VCP), a skin-permeable ascorbate derivative, abolishes the H 2 S-induced hyperalgesia and paclitaxel-induced neuropathy and also partially inhibits the spinal nerve injury-induced neuropathy (13) . These findings are consistent with some clinical evidence for the decreased plasma vitamin C levels in post-herpetic neuralgia patients (33, 34) and for the therapeutic value of ascorbic acid in patients with post-herpetic neuralgia (33, 35) or with complex regional pain syndrome after wrist fractures (36) . Together, it is likely that vitamin C acts as a modulator of Ca v 3.2 T-channels to suppress excessive sensitization of nociceptors.
There is also much evidence for involvement of Tchannels in diabetic neuropathy. Upregulation of Tchannel current density has been shown in DRG cells isolated from diabetic Bio-Bred/Worchester (BB/W) rats and from rats with streptozotocin (STZ)-induced diabetic neuropathy (4). Presynaptic Ca v 3.2 responsible for excitatory neurotransmission in the spinal dorsal horn is also functionally upregulated in the animal model of painful diabetic neuropathy (21) . It has also been reported that in vivo silencing of Ca v 3.2 in DRG reverses mechanical and thermal hyperalgesia in STZ-induced diabetic neuropathy rats (4) . Thus, the functional upregulation of Ca v 3.2 in the sensory neurons appears to cause diabetes-induced hyperexcitability and excessive neurotransmission in the peripheral and spinal endings of the nociceptors, respectively, contributing to the pathogenesis of diabetic neuropathy. Of interest is that Nlinked glycosylation of Ca v 3.2 responsible for its surface expression and enhanced activity (see Fig. 1 ) is linked to glucose elevations (16) , as mentioned in Section 2.3, which might be involved in the etiology of diabetic painful neuropathy.
Roles of T-channels in visceral pain processing
We have reported, for the first time, that Ca v 3.2 T-channels play a critical role in processing of visceral pain in the colon and pancreas (7, 8) . Intracolonic (i.col.) administration of NaHS, an H 2 S donor, to mice triggers visceral nociceptive behavior accompanied by referred hyperalgesia, which are suppressed by a T-channel inhibitor (7) and also by silencing of Ca v 3.2 (37). The nociceptive effect of i.col. NaHS/H 2 S is blocked by pretreatment with ZnCl 2 , and i.col. administration of Zn 2+ chelators causes T-channel-dependent colonic pain and referred hyperalgesia (9). As described in Section 2.1., therefore, the luminal H 2 S might interact with Zn 2+ bound to His 191 of Ca v 3.2 and cancel Zn 2+ inhibition of the channel functions, leading to facilitation of Ca v 3.2 functions and subsequent colonic pain (see Fig. 1 ). The impact of Ca v 3.2 on colonic pain signaling is supported by a recent report from an independent group showing involvement of Ca v 3.2 in butyrate-induced colonic hypersensitivity to colorectal distention in the rat, a model for irritable bowel syndrome (IBS) (38) . Similarly, activation/sensitization of Ca v 3.2 by endogenous H 2 S formed by CSE plays critical roles in pancreatic pain accompanying cerulein-induced pancreatitis (8) and in bladder pain accompanying cyclophosphamide-induced cystitis (39) . Interestingly, in these pancreatic and bladder pain models, CSE protein is upregulated in the pancreatic and bladder tissues, respectively (8, 40) . Upregulation of Ca v 3.2 protein is also detectable in the DRG in the latter model (39) . Collectively, Ca v 3.2 regulated by endogenous H 2 S may serve as a novel therapeutic target for treatment of various types of visceral pain. Apart from its role in visceral nociceptive processing, excitation of sensory neurons following H 2 Sinduced Ca v 3.2 activation underlies bladder inflammation in mice treated with cyclophosphamide (39), but exerts colonic mucosal cytoprotection in rats with 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis (40) . The H 2 S/Ca v 3.2 system would thus appear to play bidirectional roles in inflammation, in addition to pronociceptive roles, through neuronal excitation in internal organs. In contrast to involvement of Ca v 3.2 in nociceptor excitation, there is evidence that thalamic Ca v 3.1 plays an anti-nociceptive role in visceral pain signaling (41) . However, the roles of Ca v 3.1 in the primary afferents and of Ca v 3.3 are still largely open to question.
Conclusion
Among three T-channel isoforms, Ca v 3.2 has been best characterized in relation to pain signaling. As described so far, modulation of channel activity or subcellular location of Ca v 3.2 by extracellular or intracellular molecules is associated with the pathophysiology of persistent pain as well as epilepsy. Considering recent evidence that transcriptional expression of Ca v 3.2 is regulated positively by early growth response 1 (Egr1) and negatively by repressor element 1 (RE-1) proteinsilencing transcription factor (REST) (42) , abnormal regulation of transcriptional expression of Ca v 3.2 may also underlie chronic pain, as Ca v 3.2 protein is upregulated in the DRG of the rat with spinal nerve injuryinduced neuropathic pain (28) . Together, the development of selective inhibitors of Ca v 3.2 T-channels is an urgently needed for clinical application as analgesics or for research use as pharmacological tools. T-channel inhibitors with low blood-brain barrier (BBB) permeability might be useful as analgesics, since they might target T-channels expressed in the peripheral endings of nociceptors without causing central side effects. In addition, because the heart expresses both Ca v 3.1 and Ca v 3.2 isoforms, Ca v 3.2-selective T-channel inhibitors, if any, could reduce side effects on the heart. Thus, T-channel inhibitors with Ca v 3.2-selectivity and low BBB permeability would be ideal and useful as analgesics for intractable persistent pain resistant to gabapentin and pregabalin, currently available potent medicines for neuropathic pain, that inhibit high-voltage-gated Ca 2+ channels by interacting with a 2 d subunits, but not T-channels.
